Stocks and Investing Stocks and Investing
Tue, January 3, 2023

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $73 on, Jan 3rd, 2023


Published on 2024-10-28 00:42:55 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $85 to $73 on, Jan 3rd, 2023.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Upgraded from Strong Sell to Hold and Held Target at $16 on, Thursday, December 1st, 2022


These are the ratings of the 3 analyists that currently disagree with Raghuram


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $18 on, Wednesday, November 16th, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022
Contributing Sources